Quantbot Technologies LP Purchases Shares of 36,014 Lantheus Holdings, Inc. $LNTH

Quantbot Technologies LP purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 36,014 shares of the medical equipment provider’s stock, valued at approximately $1,847,000.

Other large investors also recently made changes to their positions in the company. Assenagon Asset Management S.A. bought a new position in shares of Lantheus in the third quarter valued at $65,654,000. Polaris Capital Management LLC acquired a new stake in Lantheus in the third quarter valued at $32,687,000. Norges Bank bought a new position in shares of Lantheus in the 2nd quarter valued at about $32,631,000. TD Asset Management Inc increased its stake in shares of Lantheus by 25.0% during the 3rd quarter. TD Asset Management Inc now owns 790,950 shares of the medical equipment provider’s stock worth $40,568,000 after purchasing an additional 158,358 shares during the last quarter. Finally, Boston Partners increased its stake in shares of Lantheus by 30.5% during the 2nd quarter. Boston Partners now owns 576,362 shares of the medical equipment provider’s stock worth $46,432,000 after purchasing an additional 134,781 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Trading Down 1.3%

Shares of NASDAQ:LNTH opened at $77.84 on Thursday. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $111.29. The business has a 50 day moving average of $68.79 and a 200-day moving average of $60.68. The company has a quick ratio of 2.51, a current ratio of 2.70 and a debt-to-equity ratio of 0.52. The stock has a market cap of $5.03 billion, a PE ratio of 23.10 and a beta of -0.11.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.50. The company had revenue of $406.79 million for the quarter, compared to analyst estimates of $367.03 million. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.The firm’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.59 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analyst Ratings Changes

LNTH has been the subject of several recent analyst reports. Mizuho raised their target price on shares of Lantheus from $72.00 to $85.00 and gave the company an “outperform” rating in a research note on Friday, February 27th. Citigroup restated an “outperform” rating on shares of Lantheus in a research note on Tuesday, February 24th. Citizens Jmp raised their price objective on Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a research report on Tuesday, February 24th. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Finally, JonesTrading cut Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Seven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.17.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.